Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSI-1187 in Advanced Solid Tumors with MAPK Mutations
NCT06239623Phase 1Recruiting
- Sponsor
- JS InnoPharm
- Start
- Apr 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JSI-1187 in solid tumor, non-small cell lung cancer (NSCLC), melanoma and 5 more, sponsored by JS InnoPharm. Primary endpoints: Adverse Events at 1 year and Serious Adverse Events at 1 year. Started Apr 2022; status: recruiting.
02
Drugs
JSI-1187
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)melanomahead and neck cancer (HNC)small bowel cancer
Beyond the preview
Go deeper on NCT06239623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239623.